Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib.

doi:10.1038/srep41371

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib.

Scientific reports - 24 Jan 2017

Cebrián Arancha, Gómez Del Pulgar Teresa, Méndez-Vidal María José, Gonzálvez María Luisa, Lainez Nuria, Castellano Daniel, García-Carbonero Iciar, Esteban Emilio, Sáez Maria Isabel, Villatoro Rosa, Suárez Cristina, Carrato Alfredo, Munárriz-Ferrándiz Javier, Basterrechea Laura, García-Alonso Mirta, González-Larriba José Luis, Perez-Valderrama Begoña, Cruz-Jurado Josefina, González Del Alba Aránzazu, Moreno Fernando, Reynés Gaspar, Rodríguez-Remírez María, Boni Valentina, Mahillo-Fernández Ignacio, Martin Yolanda, Viqueira Andrea, García-Foncillas Jesús

Abstract excerpt

Sunitinib is the currently standard treatment for metastatic renal cell carcinoma (mRCC). Multiple candidate predictive biomarkers for sunitinib response have been evaluated but none of them has been implemented in the clinic yet. The aim of this study was to analyze single nucleotide polymorphisms (SNPs) in genes linked to mode of action of sunitinib and immune response as biomarkers for mRCC. This is a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclooxygenase 2

Share to Disease-Free Survival

Share to Indoles

Share to Kaplan-Meier Estimate

Share to Kidney Neoplasms

Share to Pyrroles

Share to Sunitinib

Source

Open in PubMed Open full text

Identifiers

PMID: 28117391
DOI: 10.1038/srep41371
PMCID: PMC5259767

Genes

PTGS2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib.PMID 28117391Read ↗

Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib.Semantic proximity Read ↗

Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.Semantic proximity Read ↗

VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.Semantic proximity Read ↗

VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.Semantic proximity Read ↗

Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma.Semantic proximity Read ↗

Clinical effects of single nucleotide polymorphisms on drug-related genes in Japanese metastatic renal cell carcinoma patients treated with sunitinib.Semantic proximity Read ↗

Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients.Semantic proximity Read ↗

CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.Semantic proximity Read ↗

Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.Semantic proximity Read ↗

A Genetic Polymorphism in CTLA-4 Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma.Semantic proximity Read ↗

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.Semantic proximity Read ↗

Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.